Clinical Outcomes of Neoadjuvant Versus Adjuvant Chemotherapy on Muscle-invasive Bladder Cancer

• Main Authors: DENG Kangli, CUI Diansheng, JIA Quan'an, LIU Sanhe, HUANG Lei, WEI Shaozhong
• Format: Article
• Language: zho
• Published: Magazine House of Cancer Research on Prevention and Treatment 2019-04-01
• Series: Zhongliu Fangzhi Yanjiu
• Subjects: bladder cancer; neoadjuvant chemotherapy; adjuvant chemotherapy; cisplatin; gemcitabine
• Online Access: http://html.rhhz.net/ZLFZYJ/html/8578.2019.18.1002.htm
• ISSN: 1000-8578; 1000-8578

Objective To compare the clinical outcomes of neoadjuvant versus adjuvant chemotherapy on muscle-invasive bladder cancer patients. Methods We retrospectively reviewed the muscle-invasive bladder cancer patients who were treated with radical cystectomy plus neoadjuvant or adjuvant chemotherapy from 2009 to 2016 in Hubei Cancer Hospital. The primary endpoint was recurrence-free survival (RFS). The secondary endpoint was clinical complete response (CR). Results A total of 38 muscle-invasive bladder cancer patients were included: 22 patients received neoadjuvant chemotherapy and 16 patients received adjuvant chemotherapy. The RFS at median follow-up time was not significantly different between neoadjuvant and adjuvant groups (69.6% vs. 75.4%, P=0.223). The RFS at median follow-up time between maid patients with pT0 and non-pT0 were significantly different (100% vs. 50%, P=0.012). The incidence rates of grade 3 or 4 thrombocytopenia, anemia and neutropenia were not significantly different between the two groups (P=0.36). Conclusion There is no significant difference in RFS between neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer patients treated with radical cystectomy. No recurrence occurs in the patients who achieve pT0 in neoadjuvant chemotherapy group. Further investigations are needed to confirm our results.